Blood Cancer Journal - Table of Contents alert Volume 8 February 2018

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 8 (February 2018) In this issue Review Article Correspondence Article   Advertisement   Nature Outlook: Blood Blood is the epicentre of much biomedical research, from fighting disease to creating artificial substitutes for this vital fluid. This Outlook discusses topics such as a gene-editing treatment for sickle-cell disease and keeping the blood supply safe from pathogens. Get free access >>  Produced with support from: Grifols  Review Article   Chronic neutrophilic leukemia: new science and new diagnostic criteria Natasha Szuber & Ayalew Tefferi Blood Cancer Journal 2018 8: 10.1038/s41408-018-0049-8 Abstract | Full Text The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion Tiziano Barbui, Jürgen Thiele, Heinz Gisslinger, Hans Michael Kvasnicka, Alessandro M. Vannucchi et al. Blood Cancer Journal 2018 8: 10.1038/s41408-018-0054-y Abstract | Full Text Correspondence   Protease nexin-1 prevents growth of human B cell lymphoma via inhibition of sonic hedgehog signaling Xiangke Xin, Yunchuan Ding, Ying Yang, Xing Fu, Jianfeng Zhou et al. Blood Cancer Journal 2018 8: 10.1038/s41408-018-0063-x Abstract | Full Text CXCR4 can induce PI3Kδ inhibitor resistance in ABC DLBCL   Blood Cancer Journal 2018 8: 10.1038/s41408-018-0056-9 Abstract | Full Text Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome Chunyan Gu, Carol Holman, Ramakrishna Sompallae, Xuefang Jing, Michael Tomasson et al. Blood Cancer Journal 2018 8: 10.1038/s41408-018-0060-0 Abstract | Full Text CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival Natasha Szuber, Christy M. Finke, Terra L. Lasho, Michelle A. Elliott, Curtis A. Hanson et al. Blood Cancer Journal 2018 8: 10.1038/s41408-018-0058-7 Abstract | Full Text Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies Arnon P. Kater, Sanne H. Tonino, Marjolein Spiering, Martine E. D. Chamuleau, Roberto Liu et al. Blood Cancer Journal 2018 8: 10.1038/s41408-018-0055-x Abstract | Full Text Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts Abhishek A. Mangaonkar, Terra L. Lasho, Christy M. Finke, Naseema Gangat, Aref Al-Kali et al. Blood Cancer Journal 2018 8: 10.1038/s41408-018-0051-1 Abstract | Full Text Rac1 is a novel therapeutic target in mantle cell lymphoma Tian Tian, Chengfeng Bi, Ashley L. Hein, Xuan Zhang, Cheng Wang et al. Blood Cancer Journal 2018 8: 10.1038/s41408-018-0052-0 Abstract | Full Text Article   The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma Sara Canovas Nunes, Martina Manzoni, Marco Pizzi, Elisa Mandato, Marilena Carrino et al. Blood Cancer Journal 2018 8: 10.1038/s41408-018-0053-z Abstract | Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Blood Cancer Journal. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.